Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III add-on trial of GST-HG141 (nareclovir) in chronic hepatitis B patients with inadequate response to antiviral therapy
CTR20252780Phase 3Active
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neracorvir in Chronic Hepatitis B (CHB), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
neracorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20252780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252780.